REG - N4 Pharma PLC - Total Voting Rights

N4 PharmaAnnouncement

31/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231031:nRSe4646Ra&default-theme=true

RNS Number : 4646R  N4 Pharma PLC  31 October 2023

31 October 2023

 

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Total Voting Rights

 

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that the total number of shares in issue and total voting rights as at the
date of this announcement is 268,780,349 ordinary shares of 0.4 pence each
("Ordinary Shares").

 

The total issued share capital of the Company consists of 268,780,349 Ordinary
Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore,
the total current voting rights in the Company is 268,780,349 and this figure
may be used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

 N4 Pharma plc
 Nigel Theobald, CEO                                         Via IFC Advisory
 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                              Tel: +44(0)20 3470 0470
 Nominated Adviser and Joint Broker
 Matthew Johnson/Kasia Brzozowska (Corporate Finance)
 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                       Tel: +44(0)20 3657 0050
 Joint Broker
 Andy Thacker

 James Pope

 IFC Advisory Ltd                                            Tel: +44(0)20 3934 6630
 Financial PR
 Graham Herring
 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre-clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRNKABPABDDOKB